MetaVia (MTVA) Share-based Compensation (2015 - 2026)
MetaVia's (MTVA) quarterly Share-based Compensation came in at $71000.0 in Q4 2025, up 914.29% YoY from $7000.0 in Q4 2024, and down 76.33% on a QoQ basis from $300000.0 in Q3 2025.
MetaVia (MTVA) Share-based Compensation (2015 - 2026) Analysis & Trends
MetaVia (MTVA) has 11 years of Share-based Compensation data on file, last reported at $71000.0 in Q4 2025.
- Quarterly Share-based Compensation rose 914.29% year-over-year to $71000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $328000.0 (down 15.03% YoY) and the FY2025 annual result came in at $411000.0, down 31.5% from the prior year.
- Share-based Compensation fell to $71000.0 in Q4 2025, from $300000.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $400000.0 in Q1 2025 to a low of -$74000.0 in Q1 2023.
- A 5-year average of $150350.0 and a median of $155500.0 in 2023 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2023 — Share-based Compensation slumped 135.75% — and 2025, when it jumped 914.29%.
- Tracing MTVA's Share-based Compensation over 5 years: stood at $188000.0 in 2021, then grew by 15.96% to $218000.0 in 2022, then tumbled by 53.67% to $101000.0 in 2023, then tumbled by 93.07% to $7000.0 in 2024, then jumped by 914.29% to $71000.0 in 2025.
- The last three Share-based Compensation figures came in at $71000.0 (Q4 2025), $300000.0 (Q3 2025), and $111000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | MetaVia | 8.72 Mn | -3.92 Mn | - | 130,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 130,000.00 |
| Jun 30, 2026 | 130,000.00 |
| Dec 31, 2025 | 71,000.00 |
| Dec 31, 2025 | 71,000.00 |
| Sep 30, 2025 | 300,000.00 |
| Sep 30, 2025 | 300,000.00 |
| Jun 30, 2025 | 111,000.00 |
| Jun 30, 2025 | 111,000.00 |
| Mar 31, 2025 | 400,000.00 |
| Mar 31, 2025 | 400,000.00 |
| Dec 31, 2024 | 7,000.00 |
| Dec 31, 2024 | 7,000.00 |
| Sep 30, 2024 | 139,000.00 |
| Sep 30, 2024 | 139,000.00 |
| Jun 30, 2024 | 135,000.00 |
| Jun 30, 2024 | 135,000.00 |
| Mar 31, 2024 | 105,000.00 |
| Mar 31, 2024 | 105,000.00 |
| Dec 31, 2023 | 101,000.00 |
| Dec 31, 2023 | 101,000.00 |